Classic Recomp

Archival Status

CJC-1295 and Ipamorelin form the most widely researched GHRH/GHRP combination protocol in preclinical and early clinical peptide research. This stack optimizes natural growth hormone (GH) pulsatility through two distinct receptor pathways, producing physiological GH release patterns rather than the supraphysiological surges associated with exogenous hGH administration. CJC-1295 is a modified GHRH analogue with a Drug Affinity Complex (DAC) modification that extends its half-life from minutes to approximately 8–10 days through albumin binding. It binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and secretion. The DAC modification allows weekly or twice-weekly dosing while maintaining sustained GH axis stimulation. Research shows CJC-1295 with DAC elevates mean GH levels and IGF-1 concentrations in a dose-dependent manner without desensitization over 6-week research periods. Ipamorelin is a selective ghrelin receptor agonist (GHRP) and one of the most receptor-selective compounds in its class. Unlike earlier GHRPs (GHRP-2, GHRP-6), Ipamorelin produces minimal elevation of cortisol, prolactin, or ACTH — making it the preferred GHRP for long-term research protocols where hormonal crosstalk is a concern. Its primary mechanism is potentiation of GH pulse amplitude at the pituitary level and sensitization of somatotrophs to GHRH stimulation. The synergy between CJC-1295 and Ipamorelin is mechanistically elegant: CJC-1295 provides a sustained baseline elevation of GHRH receptor activity, while Ipamorelin amplifies individual GH pulses through the complementary ghrelin receptor pathway. The result is enhanced GH pulsatility that more closely mimics the natural 24-hour GH secretion profile — particularly the nocturnal slow-wave sleep peak — compared to either agent alone. Research applications include body composition optimization (reduced fat mass, improved lean tissue), sleep quality enhancement, recovery acceleration, and anti-aging protocols targeting GH/IGF-1 axis decline with age. Administration timing is important: most research protocols administer doses pre-sleep to align with natural nocturnal GH peaks, with some protocols adding a second morning dose for body composition goals.